Metabolic Clues From an Elite Cyclist:
Increased Performance Exhibited by a Tour de France Champion Based on
Orchiectomy-induced Hormonal Changes

Craig S. Atwood, Ph.D.[1] and Richard L. Bowen, M.D.[2]

[1]Section of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison and Geriatric Research, Education and Clinical Center, Veterans Administration Hospital, Madison, WI, 53705.

[2]Voyager Pharmaceutical Corporation, Raleigh, NC, 27615.

Running Title: Hormonal regulation of exercise metabolism

Corresponding Authors:
Craig S. Atwood, Ph.D.
University of Wisconsin-Madison Medical School
Wm S. Middleton Memorial VA (GRECC 11G)
2500 Overlook Terrace
Madison, WI 53705
(608)-256-1901, Ext. 11664 (phone)
(608)-280-7291 (fax)
csa@medicine.wisc.edu

Richard L. Bowen, M.D.
Chief Science Officer
Voyager Pharmaceutical Corp.
8540 Colonnade Center Dr.
Suite 409
Raleigh, N.C. 27615
Tel. 919-532-7471
rbowenmd@voyagerpharma.com

Abstract

This article examines the metabolic performance of an elite cyclist, Lance Armstrong, before and after his diagnosis with testicular cancer. Although a champion cyclist in 1 day events prior to his diagnosis of testicular cancer at age 25, he was not a contender in multi-day endurance cycle races such as the 3 week Tour de France. His genetic makeup and physiology (high $\dot{V}_{O2max}$, long femur, strong heavy build) coupled with his ambition and motivation enabled him at an early age to become one of the best 1-day cyclists in the world. Following his diagnosis, he underwent a unilateral orchiectomy, brain surgery and 4 cycles of chemotherapy. After recovering, he returned to cycling and surprisingly excelled in the Tour De France, winning this hardest of endurance events 6 years running. This dramatic transformation from a 1 day to a 3-week endurance champion has lead many to query how this is possible, and under the current climate, has lead to suggestions of doping as the answer to this metamorphosis. Physiological tests following his recovery indicated that physiological parameters such as $\dot{V}_{O2max}$ were not affected by the unilateral orchiectomy and chemotherapy. We propose that his dramatic improvement in recovery between stages, the most important factor in winning multi-day stage races, is due to his unilateral orchiectomy, a procedure that results in permanent changes in serum hormones. Likewise, his loss of body weight during the racing season (4-6 kg), which increases his power to weight ratio, also may be facilitated by these hormonal changes. These hormonal changes, specifically an increase in gonadotropins required to maintain serum testosterone, alter fuel metabolism; increasing hormone sensitive lipase expression and activity, promoting increased free fatty acid (FFA) mobilization to and utilization by muscles, thereby decreasing the requirement to expend limiting glycogen stores. Such changes also are associated with improvements in muscle repair and haematocrit levels. Taken together, these hormonal changes act to delay fatigue and enhance recovery. These insights provide the foundation for future studies on the endocrinology of exercise metabolism.

Scientific explanations often arise from examining interventions, deliberate or unintentional. This review examines the performance of an elite cyclist, Lance Armstrong, before and after unilateral orchiectomy. Lance Armstrong is arguably the greatest cyclist who has ever ridden. Even prior to his diagnosis with testicular cancer, he was an elite athlete who had a sporting career that most would envy. Following his well-documented recovery from the metastatic testicular cancer that almost took his life, he recovered to win the Tour de France six times and elevate himself into the kingdom of the worlds greatest athletes, some might say the greatest ever with regards to endurance sports. But, there is one question that continues to be raised with regard these exceptional performances: why this very good athlete, more adept at one day events (World Championship road race, 1993; San Sebastian Classic, 1995; Fleche Wallone, 1996) and not previously a contender in any of the long major tours (Tour de France, DNF 1993; DNF 1994; 36th 1995; DNF 1996), suddenly was able to win endurance events of 3 weeks duration (Tour de France, 1999-2004). The first glimpse of this transformation was in 1998, at the Tour of Spain, another 3-week endurance event, where he surprisingly finished 4th in an event that he had not even come close to placing in before. This was the beginning of his transformation from a winner of short (single day) races to winning the Tour de France (multi-day race that covers ~3800 km, competed in 21-22 stages over a 3 week period in the month of July), the hardest endurance sport event in the world and which he has won every year since 1999 (**Figure 1**).

Tests performed on Lance Armstrong at the University of Texas by Dr. Coyle between the age of 21 and 28 indicated an 8 % improvement in muscular efficiency (i.e. increased power generated) at a given oxygen uptake ($\dot{V}_{O2}$; (1)). While an 8% improvement in muscular efficiency might be obtainable in an untrained individual over time, such a large improvement in a trained elite athlete is rare to say the least. Furthermore, in the months leading up to each Tour de France victory, he reduced his body weight and body fat by ~ 7% (4-7 kg). Therefore, between 21 and his first Tour de

France victory at almost 28 years of age, these changes contributed to an amazing 18 % improvement in steady-state power per kilogram body weight when cycling at a given $\dot{V}_{O_2}$. This large improvement remains unexplained. This article is intended to provide a scientific explanation of the physiological factors leading to this improvement and his metamorphosis from a single day cycling champion into a 3-week cycling champion (2).

Many suggestions have been put forth to explain this transformation from a one-day cyclist into the Tour legend of today. One obvious answer to this question is the fact that between the time of developing cancer (~25 years of age) and his return and 4th place in the Tour of Spain at 27 years of age, it is well recognized that strength and endurance increase to a peak, a peak that can be maintained for around 5 years. Indeed, the vast majority of winners of major tours are between the ages of 27-32. Interestingly, of the other great tour riders, all but Miguel Indurain won a tour before the age of 25. Armstrong did finish 36th in the Tour de France in 1995, and had it not been for his cancer, he might have improved on this in 1996, to the point where he may have been a contender in 1997/1998. And one could argue that coupled with his training, starting as a competitive swimmer (ages 12-15) and competitive running and triathlon racing (ages 14-18) coupled with subsequent cycling to age 27, that there was an upward and continual improvement that would explain this major change in endurance. However, Armstrong's improvement, during this 2 to 2.5 year period, when his training and racing were severely curtailed, was not so much a continual improvement as it was a major leap forward. Especially considering that for the first 12 months following diagnosis his exercise was inconsistent and reduced (3). Then there is the fact that he won his 6th Tour at the age of 32. While riders have won the tour at 32 years of age, no 5-time Tour champion has done so.

It has been suggested that advances in training and conditioning are enabling athletes' to extend their careers and perform at higher levels. Another simple explanation is his innate physical attributes, including a $\dot{V}_{O_2max}$ = 83.8 ml/kg, long femur length, resting heart rate of 32-34 bpm and

lactate threshold = 178 bpm that could allow for these extraordinary performances (http://www.lancearmstrong.com/about_stats.htm and http://www.utexas.edu/). But these qualities don't necessarily translate into winning performances in long endurance races such as the great tours, as many who have similar qualities (for example, Oscar Freire Gomez, 3 time World Road Race Champion) would attest. In this respect, as indicated on the University of Texas Department of Kinesiology and Health Education website, Lance Armstrong 'is not a genetic freak. In testing hundreds of competitive cyclists during 20 years at the University of Texas, Dr. Coyle found two other individuals with the genetic potential comparable to Lance, as reflected in a $\dot{V}_{O2max}$ of approximately 6 liter/min. and 80 ml/kg/min., as well as a high lactate threshold and good cycling efficiency'. These results suggest another factor is responsible for these exceptional performances.

Others have suggested the demon of sports enhancing drugs, supposedly rife amongst the professional and amateur cycling ranks, as responsible for this much publicized transformation. Indeed, the Tour federation had an open enquiry into this and a well publicized, if inappropriately timed and titled book (4) last year by David Walsh and Pierre Ballester, on the eve of his 6th Tour victory cast further aspersions on Armstrong's character. This enquiry has largely been driven by the lack of a good explanation for his transformation into an all-conquering Tour rider. No such aspersions were cast on another US rider, winner of 3 Tours in the late 80's and early 90's, namely Greg Lemond. It is unlikely that Armstrong has used drugs in achieving his victories. Indeed, he has never tested positive on any of the numerous drug tests that he is required to give during the year. So what then has allowed Armstrong to excel in this the hardest endurance sport event in the world?

Specifications for a Tour Winner

There are four major factors (besides good luck) that are required in order to win a Tour de

France and that have led to Armstrong's dominance in this event. The first and most important is recovery, which as any Tour rider will attest is the key to winning a 3-week stage race. Armstrong's placing in the Tour of Spain was the turning point, a time when he realized that he could recover sufficiently from major daily exertions and to repeat these exertions day after day. The second factor, is that the Tour is usually won in the mountains, and in order to climb well, a rider has to have a high power to weight ratio, i.e. nearly all the great climbers are small. Armstrong's significant drop in weight (4-7 kg) during the racing season (after his bout with cancer), allowed him, together with his intense training regime, to develop a much higher power to weight ratio which allowed him for the first time to climb at the same rate as the best climbers in the world. The third required factor is related to the first two factors, recovery and power to weight ratio. The technical advance of developing a high cadence while training, racing and climbing limits muscle damage and the loss of muscle glycogen, allowing the same power output but with better recovery. Finally, Armstrong possesses the drive and mental toughness needed to train extremely hard. However, tremendous recovery is required in order to train hard frequently enough to excel over others. His ability to recover, coupled to his scientific training schedules, intelligence and confidence in his abilities, provides him with a distinct advantage for the Tour de France every July.

The Transformation

Clues as to what is responsible for his transformation from a 1 day to a 3-week endurance cyclist may be found in his encounter with cancer. To understand this transformation, we must first understand his treatment during his struggle with testicular cancer. Testicular cancer accounts for only about 1 percent of all cancers in males, but is the most common tumor in males between 15 and 34 years of age and afflicts ~7500 individuals per year in the US (5, 6). Lance Armstrong had an aggressive form of testicular cancer (nonseminomas) composed of 60% choriocarcinoma, 40%

embryonal, and < 1% teratoma (http://www.lancearmstrong.com/lance/online2.nsf/html/FAQ). Upon discovery of his testicular cancer in October of 1996, the therapeutic strategy decided upon was to remove the afflicted testicle (unilateral orchiectomy) and then undergo chemotherapy (3). Following the first round of chemotherapy with BEP (bleomycin, etoposide, cisplatin), it was discovered that a second surgery would be required to remove brain metastases, and this was then followed up by 3 more rounds of a platinum-based chemotherapy (VIP; vinblastine, etoposide, ifosfamide, cisplatin) over the next 3 months to remove lung and other metastases (3). The cancer and chemotherapy did not appear to have long term affects on his physiology (1). Obviously it did not affect one of the more important physiological characteristics, long femur length, nor did it appear to affect his other physiological parameters that allow for high performance such as high $\dot{V}$ $_{O_{2max}}$ (1). In essence, the underlying components of his 'engine' were not affected.

Although chemotherapy can lead to long-term affects, the removal of a testicle (unilateral orchiectomy) results in permanent physiological changes. From an endocrinological perspective, it has been shown that unilateral orchiectomy leads to altered serum levels of certain hormones that are produced as part of the reproductive axis (known as the hypothalamic-pituitary-gonadal (HPG) axis). A feedback loop between and sex steroids and inhibin production in the testes and LH and FSH production in the pituitary normally maintains an optimal balance of these hormones in the serum (**Figure 2**). Specifically, unilateral orchiectomy has been shown in many studies to lead to elevated levels of serum luteinizing hormone (LH; ~ 2-fold), follicle-stimulating hormone (FSH; ~2-fold), and prolactin (2.2-fold) while inhibin levels are decreased (~10 %) (**Table 1**; (7-11)). Serum testosterone levels post-orchiectomy are almost the same as pre-cancer levels, indicating that the remaining testicle is able to synthesize sufficient testosterone. This intriguing result suggests that other, unknown factors, determine the testosterone set-point in the bloodstream. However, like inhibin, 17β-estradiol levels also may be decreased (8), indicating that the remaining testicle is

unable to maintain serum concentrations of these hormones. The increased serum LH and FSH levels following orchiectomy are therefore likely due to the loss of negative feedback by inhibin (which normally suppresses FSH secretion), and estradiol (which appears to be the main regulator of LH secretion; (12)). These results suggest that in men, testosterone alone does not modulate LH/FSH secretion.

Serum concentrations of these hormones appear to remain constant post-surgery, at least for the first 10 years (11). The degree of gonadotropin elevation also is significantly correlated with the cumulative platinum dose, i.e. the greater the dose the greater is the response to produce gonadotropins (13). Interestingly, the median levels of LH and FSH are further elevated in those whose hCG levels are higher prior to orchiectomy (as in the case of Lance Armstrong; (3)), but the relative levels are approximately the same as those with no elevation in hCG. Specifically, LH increases from a median of 1.1 to 5.9 IU/L (5.4-fold), FSH from 0.1 to 8.7 IU/L (87-fold) and inhibin B from 56 to 75 pg/ml (1.3-fold) while testosterone decreased from 27 to 16 nM (1.7-fold; (8)), as a response to the loss of hCG.

That this axis should become dysregulated following orchiectomy is well established in the endocrinological literature (**Table 1**). In addition to the loss of a testicle, cisplatin-based chemotherapy (such as taken by Armstrong) results in even greater elevations in serum FSH and LH levels and decreases in serum testosterone levels when compared with surgery-only and radiotherapy-only treatments (11, 13, 14). This is likely a result of Sertoli (responsible for sperm production) and Leydig (responsible for testosterone production) cell atresia, an unfortunate side-effect of cisplatin chemotherapy. These increases in gonadotropins are similar to the increases observed as we go through 'andropause', the male equivalent of menopause, where the function of the testes in producing testosterone and inhibin slowly declines with age. Therefore, in the case of Lance Armstrong, the HPG axis has almost certainly become unbalanced because of the unilateral

orchiectomy and, additionally, chemotherapy of the remaining testicle would likely have led to further lowering of testes function with regard hormone production. How do such changes in serum sex hormones relate to Armstrong's improved recovery and perhaps his lower weight? The following section summarizes how muscle cells utilize fuels for energy.

Fuel Utilization and Metabolism for Exercise

There are three major sources of energy available to athletes: fat, carbohydrate and protein. The contribution of energy from protein is low (no more than 5 % in marathon runners; (15, 16)). Therefore, endurance athletes derive most of their energy needs from fat and carbohydrates. Muscle and liver store most of the body's carbohydrate, enough fuel (~400-600 g; (17, 18)) for approximately 90-120 minutes of high-intensity exercise (19). Fat stores on the other hand could supply energy needs for 60-100 h (19, 20) due to its higher energy content and abundance throughout the body compared with carbohydrates. Although fat can supply fuel for a number of days, the body utilizes a mixture of fat and carbohydrate in order to meet the ATP energy requirements of muscle cells during moderate to intense exercise for multiple reasons, including, 1). the generation of ATP per O_2 is greater for glucose (ATP:O_2 = 3.0) compared with fatty acids (ATP:O_2 = 2.8). Therefore, it is more advantageous to utilize glucose during periods of intense (anaerobic) exercise to meet energy (ATP) demands. Increases in glycolytic flux appear to decrease fat metabolism by decreasing the transport of FA into the sarcoplasma, lipolysis of intramuscular triacylglycerides by hormone-sensitive lipase (HSL), and transport of FA across the mitochondrial membrane (reviewed in (21)), 2. the rate of entry of free fatty acids (FFA) into muscle cells is dependent upon the concentration of unbound FFA in the plasma, 3). the contribution of unbound FFA in the plasma is restrained by solubility, 4). muscle extraction of plasma FFA may be limiting, 5). the contribution by intramuscular triglycerides to energy output while important, may be limiting

during extended periods of exercise (20). As a result, ß-oxidation of FFA alone cannot be mobilized rapidly enough to provide 100 % of the ATP required by muscles at higher intensity levels for sustained periods of time. Therefore, endurance athletes like runners and cyclists use a mixture of these fuels to meet their immediate energy requirements. This is not a new concept, Randle proposed over 40 years ago that FFA's compete with glucose as the major energy substrate in (cardiac) muscle (22).

The contribution of carbohydrate will vary depending upon the intensity and duration of the event. The higher the intensity and the greater the ATP requirement the greater will be the requirement for carbohydrate oxidation to make up for the short fall of ATP production from ß-oxidation of fatty acids. Energy obtained from ß-oxidation will be dependent upon both intramuscular FFA stores (23, 24) and FFA transported into myocytes from the plasma. Plasma FFA concentrations increase with exercise time, as does the level of unbound (to albumin) FFA, the fraction available for uptake by muscle cells (20, 25, 26). Therefore, the greater the length of the exercise, the higher are the levels of total and thus unbound plasma FFA and the greater the contribution of ß-oxidation to the overall ATP requirement. The limiting factor in how long an athlete can perform intense exercise is therefore going to be dependent upon the total amount and rate of utilization of carbohydrates (given the limited supply of body (primarily muscle and liver) glycogen). At high exercise intensity, dietary glucose is insufficient to maintain these stores. Therefore, the only way an athlete can accommodate the reduced availability of glucose is to increase FFA ß-oxidation, or to reduce speed. Interestingly, the utilization of carbohydrate is inversely correlated to that of FFA and falls throughout a marathon (20). However, even this increase in FFA cannot compensate for the depletion of glucose stores. Fatigue (or' hitting the wall'), is characterized by a drop in speed which is a direct result of decreased carbohydrate utilization as a result of a fall in blood glucose levels due to depletion of muscle and liver glycogen

stores and blood glucose stores (20). Declines in blood glucose are not evident in non-fatigued athletes. Fatty acid utilization is unchanged during fatigue, indicating that lipid is the preferred fuel of muscles, but is rate limiting, and that carbohydrate utilization is required for optimal times. Therefore, those athletes that can use a higher FFA/glucose ratio at any given speed (i.e. $\dot{V}_{O_2}$) for their overall energy needs will endure longer than those with a lower FFA/glucose ratio. Furthermore, athletes that don't utilize all their carbohydrate stores during an exercise period will have a greater chance of replenishing their carbohydrate stores to maximal levels compared to those that start with very low carbohydrate stores. This means exercise of a similar or greater intensity and duration can be achieved on subsequent days.

Factors that promote triglyceride utilization will therefore have a marked impact upon the time to exhaustion and recovery following intense exercise. The following sections will discuss factors that alter intramuscular utilization of triglycerides, as well as those that influence intramuscular glycogen stores.

The Effects of Hormones on Fat and Glycogen Metabolism

Fat Metabolism: The rate of FFA utilization by muscles is dependent upon the breakdown of intramyocellular fat stores and the mobilization of FFA from adipocytes and hepatocytes, although recent evidence suggests that utilization of intramyocellular stores of FFA may be as important for energy as mobilization of FFA from the blood (23, 24). Training/exercise itself increases lipolysis in muscles and plasma FFA and the reliance upon FFA for energy (27-33). This also has been illustrated in trained versus untrained animals (rats); trained animals utilize higher levels of FFA's and ketone bodies when fasted compared to untrained animals (34). This is due in part to the increased enzymatic activity and expression of two lipases, HSL in skeletal muscle and heart (35-39) and lipoprotein lipase in skeletal muscle (and adipocytes; (40)), and to increases in carnitine

palmitoyl transferase in muscle (41), which promote increased intramuscular triglyceride lipolysis (e.g. (23, 24)). HSL is expressed in all muscle fiber types, being higher in oxidative fibers than in glycolytic fibers (42, 43). HSL also is the rate-limiting enzyme for intracellular triglyceride hydrolysis in adipose tissue. HSL enzyme activities and expression are higher in adipose tissue after adrenaline treatment in trained compared with sedentary rats (44), suggesting training increases fatty acid mobilization and uptake for utilization by muscles. Whereas fatty acids liberated by adipocyte triglyceride hydrolysis are released into the bloodstream, the fatty acids produced from HSL-induced triglyceride hydrolysis in myocytes appear to be utilized by myocytes (45).

It has been suggested that HSL and LPL are activated by similar signals and act in a coordinated fashion to meet muscle energy demands: HSL hydrolyzes endogenous muscle triglycerides while LPL activity is increased in parenchymal cells in muscle and promotes triglyceride uptake (replenishment) by muscle (46). Modulation of HSL expression and activity over the short-term and long-term is complex, but appears to be modulated by several interacting stimuli including muscle contraction and hormones (see below). With regard muscle contraction, HSL activity appears to be modulated by the frequency and duration of exercise as a result of changes in glycogen content (low glycogen induces HSL activity), free AMP, activation of AMP kinase and phosphorylation of inhibitory sites on HSL (38, 39). It has been suggested that HSL also may be allosterically inhibited during prolonged exercise (or with rest) as a result of the accumulation of long-chain fatty acyl-CoA (38).

These changes indicate an adaptive response to endurance training (47) that decreases glycogenolysis in muscles and spares glycogen reserves. Conversely, detraining leads to an increased reliance on carbohydrate metabolism during exercise, as shown by a higher exercise respiratory exchange ratio, and lowered lipase activity, GLUT-4 content, glycogen level and lactate threshold (48). Hence, well-trained individuals using a higher proportion of FFA for energy will

spare more muscle and liver glycogen, and together with their higher basal glycogen reserves, can therefore maintain a similar level of intensity for a longer period of time compared with untrained individuals.

This shift from carbohydrate to fat utilization with training (27) also is observed with the hormonal changes associated with the menopause and andropause (the male equivalent of menopause). As mentioned above these hormonal changes (decreased sex steroids and increased gonadotropins) are similar to those that occur following orchiectomy and lead to a more atherogenic lipid profile: increased triglycerides, LDL-cholesterol and its smaller dense subfractions and decreased HDL- and HDL2-cholesterol (reviewed in (49)). Interestingly, dysregulation of triglyceride-lipolysis such as occurs with menopause/andropause is linked to increased mobilization and elevations in the concentration of circulating FFA (50-53). The increase in muscle lipolytic activity with aging (45) may explain age-related increases in endurance.

Experimental evidence indicates the hormonal changes associated with menopause/andropause are responsible for these changes in circulating FFA. For example, the fetal form of the gonadotropin LH is human chorionic gonadotropin (hCG), which promotes the expression of HSL (54), and therefore the lipolysis of triglycerides in muscle and fat stores. Furthermore, declines in testosterone or 17ß-estradiol increase HSL (55, 56) in adipocytes and the synthesis and activity of hepatic lipase that regulates the rate of synthesis of structural apolipoproteins for VLDL and HDL (57-59). Conversely, 17ß-estradiol decreases systemic FFA release in postmenopausal women (60). Additionally, testosterone and dihydrotestosterone inhibit lipid uptake and lipoprotein-lipase (LDL) activity and expression in adipocytes, but only LPL expression appears to be mediated via the androgen receptor suggesting that other hormones such as LH might regulate HSL activity (55). Recently, another lipase, adipose triglyceride lipase, has been shown to be important in the mobilization of fat from adipose tissues (61). The hormonal regulation of the expression/activity of

this lipase has not been determined.

Another orchiectomy induced hormone-induced metabolic change that would promote increased ATP production and glycogen sparing may come from the increased HSL-induced hydrolysis of adipocyte triglycerides and the uptake of fatty acids by the liver and there conversion into ketone bodies. Production of ketone bodies has two major benefits, 1) they produce a large amount of ATP and it has been reported that LH and prolactin (also increased with orchiectomy; Table 1) promote the activity of a key enzyme (D-3-hydroxybutyrate dehydrogenase) involved in ketone synthesis (62), 2). many extra hepatic tissues utilize ketone bodies in the fasted state with the advantage that glucose is "spared" for more vital tissues like the brain (63). The production of ketones by the liver increases both during prolonged exercise and during recovery from exercise (64), suggesting the body perceives starvation and exercise to be similar. Exercise also is known to increase ketone body utilization in skeletal muscle (65), although the contribution of hormonal changes to this increased production and utilization is unknown. It is interesting to speculate whether this increase in ketone production lessens lactate production, i.e. increases the lactate threshold as reported for Lance Armstrong (1).

Carbohydrate Metabolism:

Training increases muscle stores of glycogen (66). Muscle contraction apart from increasing HSL also induces a parallel increase in glycogen phosphorylase (36) for glycogenolysis. In non-active post-menopausal women, reproductive hormonal changes are associated with reduced pancreatic insulin secretion, impaired insulin elimination leading to elevated insulin concentrations and a progressive increase in insulin resistance (67, 68). This can lead to impaired glucose tolerance and diabetes mellitus (found in nearly 20% of women aged 55 to 65 years; (49)). It is less clear what affect the altered hormonal profile following unilateral orchiectomy has on serum insulin and carbohydrate metabolism in an athlete. However, an athlete that is rapidly utilizing, rather than

storing fuels, is unlikely to have insulin resistance and suffer these problems. Indeed, exercise has been shown to prevent these hormone-related changes and almost completely reverse diabetes II. Since castration has been shown to decrease insulin expression and serum concentrations (69, 70), but results in impaired insulin clearance on the other hand, it is possible that serum insulin concentrations also are elevated following unilateral orchiectomy, as noted for bilateral orchiectomy (71). If insulin levels were to be increased following unilateral orchiectomy, this would enhance glucose and FFA uptake by muscles.

Coupling Orchiectomy-induced Changes in Serum Hormones with Fuel Utilization, Muscle Repair and Erythroid Function

Benefits of Orchiectomy-induced Lipid Changes to Recovery: At times when the serum gonadotropin to estrogen ratio is high (pregnancy, neonatal life, orchiectomy and menopause/andropause), HSL expression is increased leading to increased fat mobilization from the liver and adipose tissues. This ratio is optimal during pregnancy and neonatal life in order to supply the developing fetus/baby with fatty acids. However, in sedentary individuals, together with the other changes mentioned previously, this mobilized fat is not utilized but is laid down in intra-abdominal fat and muscle reserves resulting in the well-described increase in body weight with aging (72-76). This increase in body weight is highly correlated with age-related diseases.

During exercise, the utilization of triglycerides is dependent upon lipolysis of myocellular and extra-myocellular stores of triglycerides. Therefore, while these hormone-induced atherogenic changes in the lipid profile may not be conducive to health in a sedentary individual, *in an athlete, increased gonadotropin-induced HSL expression would promote increased fatty acid utilization by, and mobilization to, muscles, and would decrease the requirement to expend limiting glycogen stores* (**Figure 3**). The capacity for an individual to endure during exercise will depend upon both

the level of FFA to glycogen utilized at any given intensity ($\dot{V}_{O_2}$) together with the rate of increase in this ratio during exercise, and the rate of glucose uptake during exercise. In the case of Lance Armstrong, increased serum gonadotropin levels would result in a higher basal FFA serum concentration and muscle triglyceride utilization that would be elevated at rest and at any given exercise intensity compared with other athlete's. And, as mentioned before, athletes capable of utilizing a higher ratio of fat to glycogen at any given exercise intensity will have greater endurance than those who must utilize a lower ratio of fat to glycogen. In this respect, although contractions increase HSL activity, there appears to be an additive effect of hormones on contraction-induced increases in HSL activity (43). Additionally, since HSL activity also is greater at rest, such athletes would have a higher utilization of FA to glucose, which would spare glucose and enhance glycogenesis. Finally, these altered hormone levels might act to promote fatty acid synthesis allowing replenishment of intramuscular triglyceride stores; there is some evidence indicating prolactin increases acetyl-CoA carboxylase activity and fatty acid synthesis in mammary epithelial cells (77, 78), and fatty acid synthase, and lipoprotein lipase.

The advantages of increased fat utilization on performance are highlighted by the results of a chronic (4 week) eucaloric ketogenic diet (high fat) on submaximal exercise performance in trained cyclists. The mean ergometer endurance time for continuous exercise to exhaustion at 62-64% $\dot{V}_{O_2max}$ on this diet was 151 min. compared to 147 min. prior to the ketogenic diet (79). Despite a drop in RQ (from 0.83 to 0.72), a 3-fold drop in glycogen oxidation and a 4-fold reduction in muscle glycogen, the endurance of these well-trained cyclists was slightly better. These results indicate that aerobic endurance exercise by well-trained cyclists is not compromised by 4 weeks of ketosis. Thus, physiological adaptations to a high fat diet conserve limited carbohydrate stores (glucose and muscle glycogen) and make fat the predominant muscle substrate at submaximal exercise. Therefore, enhanced HSL-induced FFA utilization by muscle during submaximal exercise would similarly be

expected to spare body stores of glycogen and glucose.

Benefits of Orchiectomy-induced Muscle Repair to Recovery: Although less studied, another component of recovery, the ability of muscle fibers to repair between exercise bouts, also has been shown to be significantly impacted by HPG hormones. Alpha-actin expression has been shown to increase in luteal cells with hCG treatment (80) and HPG hormones affect fast fiber size and type IIb myosin heavy chain expression in the rat (81). Furthermore, LH has been shown to increase junction and repair strength (above that of training alone) of collateral ligaments in rats whose ligaments had been surgically repaired (82).

Benefits of Orchiectomy-induced Erythroid Function to Performance: Finally, it has been demonstrated that a the HPG hormone profile such as that induced by orchiectomy or following menopause leads to a statistically significant increase in the circulating concentrations of red blood cells and hemoglobin (83-85). Such changes would have obvious effects for aerobic metabolism and lactate metabolism, and sparing glycogen utilization.

Benefits of Orchiectomy-induced Recovery to Performance: Recovery comprises refueling the muscles glycogen (and fat) stores and repairing damage to muscle cells sustained as a result of the exertion. Therefore, in addition to the above sparing of glycogen reserves (i.e. until required later in a stage), preservation of glycogen reserves during stages will enable quicker recovery of glycogen reserves to maximal levels from strenuous exercise, allowing for more complete recovery for the next days energy requirements. This more complete recovery (coupled with increased muscle repair) also affords the athlete with the ability to undertake longer and more intense exercise sessions, more often, which over the long term results in an individual who can train to a higher level. Indeed, most elite cyclists cannot handle the huge daily workloads of Lance Armstrong leading up to the Tour de France each year, i.e. what is perceived as training hard is relative to your ability to be able to recover. Armstrong's high cadence also may lessen muscle damage, helping

aid recovery.

In summary, Lance Armstong's high gonadotropin to sex steroid ratio will 1). increase serum FFA and the utilization of FFA by muscles, sparing glycogen reserves, 2). increase muscle repair and 3). increase haematocrit and hemoglobin concentrations, all of which will promote increased endurance and recovery.

HPG Hormones Modulate Body Weight and Composition

A major component to Armstrong's success has been his ability to reduce body fat and therefore body weight during the racing season (4-7 kg), allowing a greater power to weight ratio, particularly useful in the mountains and time trials where time gained and lost determines who wins the tour. The increased mobilization of fats for use in energy metabolism might also explain the decrease in body weight (fat) of Lance Armstrong following unilateral orchiectomy.

In sedentary individuals, decreasing serum testosterone and increased LH also promotes muscle catabolism leading to a decrease in muscle strength and lean mass (sacropenia) (73-75, 86). Lance Armstrong does not appear to have lost muscle mass, likely due to the fact that individuals who undergo unilateral orchiectomy have normal serum testosterone post-treatment, coupled with his intense exercise program. This is supported by the observation that four well trained men who pulled 130 kg sleds over 500 km across the inland glacier of Greenland in 1988 (retracing the route of the famous arctic explorer Fridtjof Nansen from 1888) over a period of 42 days (87) displayed an increased lean body mass despite the lowered serum testosterone and increased gonadotropin levels brought about by the intense physical effort and cold and energy deficits (87). This suggested that exercise prevents sarcopenia despite changes in serum sex hormones. Irrespective of this, muscle mass does not necessarily equate with muscle strength (http://www.dolfzine.com/page216.htm). Moreover, exogenous testosterone does not improve performance in endurance events (88).

Muscle Type and Composition – Affects of Hormones

Intriguingly, hormonal changes associated with castration have been shown to increase the size, but not the number, of type II muscle fibers (usually of the A subtype) in humans after menopause/andropause and animals after castration, but these changes appear to be muscle specific, while type IIB appears to decrease in size (89-91). Generally there is no change in type I fibers. Type 1 fibers contain myoglobin, numerous mitochondria, a rich capillary supply close to the periphery of the fiber that provides a rich supply of oxygen and nutrients and slow acting myosin ATPases. Type I fibers possess a high capacity for oxidative metabolism, utilize more FFA, are extremely fatigue resistant and specialized for the performance of repeated contractions over prolonged periods such as endurance cycling events. Type II muscle fibers contain little myoglobin, have fewer mitochondria, a poorer capillary supply, but greater glycogen and phosphocreatine stores and rapidly acting myosin ATPases. A high activity of glycogenolytic and glycolytic enzymes endows type 2 fibers with a high capacity for rapid (but relatively short-lived) ATP production in the absence of oxygen (anaerobic capacity). As a result lactic acid accumulates quickly in these fibers and they fatigue rapidly. Therefore, these fibers are suited for delivering rapid, powerful contractions for brief periods such as when climbing hills (http://www.medicdirectsport.com/exercisetheory/ default.asp?step=4&pid=48).

Type I fibers are required for long distance cycling events while riding at moderate speeds, however the requirement for type 2 fibers increases during times of more intense anaerobic exercise (i.e. like climbing mountains, time trials). The vastus lateralis muscle (part of the quadriceps muscle group) of successful marathon runners has been shown to have a high percentage (about 80%) of type 1 fibers, while that of elite sprinters contains a higher percentage (about 60%) of the type 2 fast-twitch fibers. In this context, better endurance performance in horses is correlated with a higher percentage and relative areas of type I and type IIA fibers and lower percentages and relative areas

of type IIB fibers than moderate performers (92). As discussed above, type I fibers do not appear to change with castration, however, type IIA fibers increase in size. Interestingly, prolonged endurance training makes type II fibers more like type I fibers and is suggested to explain the higher pedaling cadence of Armstrong pre- and post-cancer (~85-95 rpm to 105-110 rpm; (1)). Although the effects of these changes on athletic performance have yet to be fully elucidated it is possible that Lance Armstrong has not only optimized fuel utilization for type I fibers (increased FFA availability), but enhanced his anaerobic capacity as a result of an increase in the size of type II muscle fibers required during intense exercise.

Exercise-induced Changes in Serum Hormones – Impact on Energy Metabolism

Intense exercise regimes are well known to alter the concentration of serum hormones, particularly GnRH and LH pulsatility, leading to amenorrhea in some endurance trained women (e.g. (93-95)). Recent studies have suggested that it is not so much the 'stress' of exercise, but low energy availability that lowers serum gonadotropins and sex steroids (87, 96, 97). In particular, insufficient fuel (glycogen/glucose and FFA) leads to a decrease in the release of LH from the pituitary (decreased LH pulsatility; (97, 98)). The bodies' 'sensing' that it does not have enough food (i.e. starvation) is well known to suppress reproductive hormones (and increase longevity; (99)). Exercise also has been shown to decrease serum leptin levels (100, 101), an adipocyte-derived protein hormone that is a marker of fat accumulation. Therefore, decreased glucose/FFA availability such as following intense exercise or fasting/starvation may therefore act via decreased leptin secretion to decrease GnRH and LH pulsatility (102). Put another way, high GnRH, LH and FSH is associated with increased glycogen and fat utilization since the reproductive environment is good. Thus, the increase in serum LH with age may be due not only to the decreased negative feedback of testosterone and increased activin levels that result from the decline in gondadal function but may be accentuated by the increased release of leptin from accumulating adipose tissue following

menopause and andropause.

The high intensity exercise of the Tour de France might be expected to lead to a decrease in leptin, gonadotropin and sex steroid production, and therefore lower serum LH and testosterone levels. In this respect, the ability to consume and metabolize enough food by Tour riders who must consume 6000-6500 calories/day may limit recovery and suppress reproductive hormones. Indeed, plasma testosterone, LH and insulin, and muscle glycogen in liver, decline after exercise (1-7 h treadmill) and fasting (24-72 h) at least in male rats. Since hCG increased plasma testosterone levels in rats in the course of exercise and starvation, the decrease in plasma LH may be responsible for the decrease in plasma testosterone, which is time-related with the decrease in glycogen stores (98). This suggests that glycogen stores regulate LH and testosterone secretion, and those individuals with higher glycogen (and fat) stores will have higher reproductive hormones. Additionally, the mixture of FFA to carbohydrates utilized is likely dependent upon the ratio of LH to sex steroids. In this respect, at any particular level of stress, Lance Armstrong would be expected to have a higher ratio. Indeed, such changes in the ratio of LH to testosterone might explain the increased endurance of male athletes as they age since the balance of sex steroids to gonadotropins begins to change in the mid-twenties. Younger athletes (i.e. 20 years) are generally not capable of matching the endurance of 30 to 40 year old athletes. Studies also have shown that training partially attenuates the decrease in serum testosterone associated with starvation (i.e. glucose utilization) in rats compared with untrained animals (40% compared to 300% decrease in testosterone; (34)), indicating a training component to the regulation of sex hormone levels, that might be due to the increased utilization of FFA and sparing of glycogen, suggesting glycogen stores are the primary regulator of reproductive hormones. Thus, the level of LH to testosterone may modulate FFA to glycogen utilization in humans, and therefore sporting endurance.

Consequences of Orchiectomy and Chemotherapy

The cure rate for testicular cancer is high, and reoccurrence is highly curable. After three years without recurrence, the probability that a patient is cured is greater than 95 percent (103). Recovery of spermatogenesis after treatment may be long, in some patients lasting more than 5 years (104). Interestingly, elevated hCG is correlated with low sperm concentration and quality parameters which improve following orchiectomy (10). Sufficient androgen production is seen in the majority of the patients but some patients do suffer from testosterone deficiency. The effect of chemotherapy on Leydig cell function seems to be dose dependent (105). In some patients with germ cell tumors, a compensated insufficiency of the function of the Leydig cells was still observed up to 60 months after chemotherapy. Of these patients 68% showed elevated FSH levels, which reflected a functional insufficiency of the Sertoli cells with impaired spermatogenesis (14). Altered hormonal levels following unilateral orchiectomy, radiation and chemotherapy lead to impaired spermatogenesis and Leydig cell function and are persistently impaired in the majority of testicular cancer patients treated with radiotherapy or with more intensive (6 cycles) chemotherapy (7).

Fortunately, it would appear that Lance Armstrong is cured of testicular cancer. However, the dysregulation of the HPG axis, as a result of his treatment, can lead to many age-related diseases (e.g. heart disease, diabetes II, cancer, Alzheimer's disease etc). Alterations in serum hormones obviously induce altered energy metabolism as discussed above. But these hormones also regulate cell division, and in the dysregulated hormonal milieu following menopause/andropause or castration, we have proposed that these hormones control aging via cell cycle signaling; promoting growth and development early in life in order to achieve reproduction, later in life, in a futile attempt to maintain reproduction, they become dysregulated and drive senescence (99). This increase in gonadotropin production would elevate the likelihood of future cancers, and would cause a general increase in the rate of aging. This typically occurs after menopause and later in andropause, as seen

by the increase in cancers. However, unilateral orchiectomy exposes an individual to this altered hormonal signaling decades prior to others. Interestingly, the fetal form of LH, hCG, is a marker of cancer progression, the higher the serum concentration the greater the cancer burden. It is likely that this hormone is produced by the cancer to drive cell division and alter energy metabolism to allow for cancer growth.

How might an orchiectomy patient reduce the risk of these age-related diseases (including cancer reoccurrence)? Maintaining fitness to limit fat accumulation is an obvious strategy and should decrease risk of developing many age-related diseases. The re-establishment of the HPG hormones back to levels of a healthy reproductive male would be another important protective strategy. This would involve giving back both testosterone and inhibin. Testosterone supplementation has been shown to improve the quality of life for men with testosterone deficiency.

The Armstrong Advantage

While it is perceived that cancer, surgeries and chemotherapy might actually impede sports performance, the above evidence would suggests that unilateral orchiectomy promotes physiological maturation and athletic performance by enhancing fuel metabolism, muscle repair and erythroid function. Therefore, Armstrong's athletic advantage is most likely due to his unique genetic and physiological makeup coupled to the endocrinological changes induced by his unilateral orchiectomy, not drugs as suspected by certain reporters, cycling enthusiasts and French cycling authorities. Indeed, the use of drugs such as erythropoietin would be foolish given that there is evidence to suggest this mitogen can promote tumor growth (106, 107).

Lance Armstrong's misfortune in developing testicular cancer has provided many clues as to the mechanisms that promote endurance, and suggest that the genetic makeup of an endurance champion may be mediated via signaling through hormones and hormone receptors of the HPG axis.

Measurement of the serum ratio of gonadotropins (LH, hCG, FSH) to sex steroids (androgens and estrogens) before, during and after exercise, together with fuel utilization parameters would determine if this is a common trait in elite endurance athletes, and the endurance potential of athletes.

Artificially modulating these hormones for increasing human endurance performance is however difficult due to the short half-life of LH in blood.   While recombinant hCG has a longer half-life, it would be easily detectable from endogenous hCG. And only the foolish would undergo orchiectomy or administer drugs to alter sex hormone levels to enhance performance in endurance sports given the long-term risks to health and longevity (99). *We do not recommend unilateral orchiectomy as a performance enhancing modality.*

Table 1: Serum hormone concentrations pre- and post-orchiectomy.

Study	Chemo-therapy (cycles)	Post-surgery (years)	LH (IU/L) Before	After	FSH (IU/L) Before	After	Prolactin (ng/ml) Before	After	Inhibin B (pg/L) Before	After	Testosterone (nM) Before	After
1	3-4	3	9.5	10.3	7.7	11.1	-	-	-	-	7.0	5.1
2	?	0.42	3.1	5.2*	5.7	10.0*	-	-	108	95*	15	15
3[@]	None	0.25 1	5.6	22.6* 9.9	2.2	17.7* 8.4*	8.6 7.7	9.8	-	-	5.7	16.6* 18.9*
4	2-3 (PVB, PEB or PE)	>1	3.2	6.4*	4.0	8.9*	10.7	23.8*	-	-	16.5	18.8
5	Cisplatin	>10	3.5	5.5*	-	-	-	-	-	-	17.1[#]	16.7

1 = Palmieri et al., 1996; 2 = Petersen et al., 1999a; 3 = Zarrilli et al., 2000; 4 = Tomomasa et al., 2002; 5 = Nord et al., 2003. * Significantly different ($P \leq 0.05$). All studies were of unilateral orchiectomy. [#] Indicates control rather than pre-orchiectomy value. [@]Patients had gynaecomastia – orchiectomy eliminated estrogen secretion and lead to elevations in gonadotropins as well as the large elevation in serum testosterone back to normal levels.

FIGURES

Figure 1: **Lance Armstrong.** Lance Armstrong climbing Alpe d'Huez in the time trial in the 2004 Tour de France. Photo courtesy of Graham Watson.

Figure 2: **The Hypothalamic-Pituitary-Gonadal Axis.** The concentration of each of the HPG axis hormones is regulated by complex feedback loops. The loop is initiated in the periphery by activins which stimulate the hypothalamus to release gonadotropin releasing hormone (GnRH). This in turn stimulates the anterior pituitary to secrete the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH). These then bind to receptors on the gonads and stimulate oogenesis/spermatogenesis, as well as sex steroid and inhibin production. The sex steroids feedback to the hypothalamus and pituitary, resulting in a decrease in gonadotropin secretion. Inhibin, produced primarily in the gonads in association with oogenesis/spermatogenesis, is known to bind to and inactivate activins. Activins stimulate GnRH and gonadotropin secretion. Inhibin therefore indirectly controls gonadotropin synthesis. Follistatin, expressed in many different tissues also inhibits activins.

Figure 3: **Schematic of Biochemical Changes Following Unilateral Orchiectomy.** Orchiectomy induces changes in the concentrations of serum HPG hormones that alter energy metabolism: increasing hormone-sensitive lipase and lipoprotein lipase expression and activity thereby promoting increased FFA mobilization to, and utilization by, muscles. This has two affects, 1). to spare limiting glycogen stores and allowing for greater endurance and recovery, and 2). to decrease body weight which increases power to weight ratio, leading to increased performance.

Figure 1:

Figure 2

Figure 3

Publications

1. Coyle EF 2005 Improved muscular efficiency displayed as Tour de France champion matures. J Appl Physiol 98:2191-6

2. Atwood CS, Bowen RL 2005 The Armstrong Advantage: Unilateral Orchiectomy-induced Increases in the Ratio of Gonadotropins to Testosterone Delay Fatigue and Enhance Recovery in Elite Athletes - Would You Give Your Left Testicle to Win the Tour de France? The Endocrine Society P1:397

3. Armstrong L 2000 Lance Armstrong, It's Not About the Bike. My Journey Back to Life. Berkley Books, New York

4. Walsh D, Ballester P 2004 L.A. Confidential, the Secrets of Lance Armstrong. La Martiniere

5. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF, Jr. 1995 Recent cancer trends in the United States. J Natl Cancer Inst 87:175-82

6. Landis SH, Murray T, Bolden S, Wingo PA 1998 Cancer statistics, 1998. CA Cancer J Clin 48:6-29

7. Palmieri G, Lotrecchiano G, Ricci G, et al. 1996 Gonadal function after multimodality treatment in men with testicular germ cell cancer. Eur J Endocrinol 134:431-6

8. Petersen PM, Skakkebaek NE, Rorth M, Giwercman A 1999 Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. J Urol 161:822-6

9. Zarrilli S, Lombardi G, Paesano L, et al. 2000 Hormonal and seminal evaluation of Leydig cell tumour patients before and after orchiectomy. Andrologia 32:147-54

10. Tomomasa H, Oshio S, Ashizawa Y, et al. 2002 Gonadal function in patients with testicular germ cell tumors. Arch Androl 48:405-15

11. Nord C, Bjoro T, Ellingsen D, et al. 2003 Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 44:322-8

12. Bilezikian JP, Morishima A, Bell J, Grumbach MM 1998 Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599-603

13. Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ 1996 Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 73:1108-14

14. Brennemann W, Stoffel-Wagner B, Helmers A, Mezger J, Jager N, Klingmuller D 1997 Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. J Urol 158:844-50

15. Plante PD, Houston ME 1984 Effects of concentric and eccentric exercise on protein catabolism in man. Int J Sports Med 5:174-8

16. Plante RI, Houston ME 1984 Exercise and protein catabolism in women. Ann Nutr Metab 28:123-9

17. Essen B 1977 Intramuscular substrate utilization during prolonged exercise. Ann N Y Acad Sci 301:30-44

18. Newsholme E 1983 Control of metabolism and the integration of fuel supply for the marathon runner. Human Kinetics Publishers, Inc., Champaign

19. Newsholme E, Leech A 1983 Biochemistry for the medical sciences. John Wiley and Sons, Chichester

20. Callow M, Morton A, Guppy M 1986 Marathon fatigue: the role of plasma fatty acids, muscle glycogen and blood glucose. Eur J Appl Physiol Occup Physiol 55:654-61

21. Jeukendrup AE 2002 Regulation of fat metabolism in skeletal muscle. Ann N Y Acad Sci 967:217-35

22. Randle PJ, Newsholme EA, Garland PB 1964 Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 93:652-65

23. Coyle E 2000 Physical activity as a metabolic stressor. Am J Clin Nutr. 72:512S-20S

24. Zderic T, Davidson C, Schenk S, Byerley L, Coyle E 2004 High-fat diet elevates resting intramuscular triglyceride concentration and whole body lipolysis during exercise. Am J Physiol Endocrinol Metab 286:E217-25

25. Gollnick PD 1977 Free fatty acid turnover and the availability of substrates as a limiting factor in prolonged exercise. Ann N Y Acad Sci 301:64-71

26. Newsholme EA 1977 The regulation of intracellular and extracellular fuel supply during sustained exercise. Ann N Y Acad Sci 301:81-91

27. Koivisto VA, Soman VR, Defronzo R, Felig P 1980 Effects of acute exercise and training on insulin binding to monocytes and insulin sensitivity in vivo. Acta Paediatr Scand Suppl 283:70-8

28. Friedmann B, Kindermann W 1989 Energy metabolism and regulatory hormones in women and men during endurance exercise. Eur J Appl Physiol Occup Physiol 59:1-9

29. Keim NL, Barbieri TF, Van Loan MD, Anderson BL 1990 Energy expenditure and physical performance in overweight women: response to training with and without caloric restriction. Metabolism 39:651-8

30. Keim NL, Belko AZ, Barbieri TF 1996 Body fat percentage and gender: associations with exercise energy expenditure, substrate utilization, and mechanical work efficiency. Int J Sport Nutr 6:356-69

31. Phillips SM, Green HJ, Tarnopolsky MA, Heigenhauser GF, Hill RE, Grant SM 1996 Effects of training duration on substrate turnover and oxidation during exercise. J Appl Physiol 81:2182-91

32. Langfort J, Ploug T, Ihlemann J, Holm C, Galbo H 2000 Stimulation of hormone-sensitive lipase activity by contractions in rat skeletal muscle. Biochem J 351:207-14

33. Jeukendrup AE 2003 Modulation of carbohydrate and fat utilization by diet, exercise and environment. Biochem Soc Trans 31:1270-3

34. Guezennec CY, Ferre P, Serrurier B, Merino D, Aymonod M, Pesquies PC 1984 Metabolic effects of testosterone during prolonged physical exercise and fasting. Eur J Appl Physiol Occup Physiol 52:300-4

35. Oscai LB 1983 Type L hormone-sensitive lipase hydrolyzes endogenous triacylglycerols in muscle in exercised rats. Med Sci Sports Exerc 15:336-9

36. Langfort J, Ploug T, Ihlemann J, et al. 1998 Hormone-sensitive lipase (HSL) expression and regulation in skeletal muscle. Adv Exp Med Biol 441:219-28

37. Watt MJ, Heigenhauser GJ, O'Neill M, Spriet LL 2003 Hormone-sensitive lipase activity and fatty acyl-CoA content in human skeletal muscle during prolonged exercise. J Appl Physiol 95:314-21

38. Watt MJ, Spriet LL 2004 Regulation and role of hormone-sensitive lipase activity in human skeletal muscle. Proc Nutr Soc 63:315-22

39. Roepstorff C, Vistisen B, Donsmark M, et al. 2004 Regulation of hormone-sensitive lipase activity and Ser563 and Ser565 phosphorylation in human skeletal muscle during exercise. J Physiol 560:551-62

40. Nikkila EA, Taskinen MR, Rehunen S, Harkonen M 1978 Lipoprotein lipase activity in adipose tissue and skeletal muscle of runners: relation to serum lipoproteins. Metabolism 27:1661-7

41. Costill DL, Fink WJ, Getchell LH, Ivy JL, Witzmann FA 1979 Lipid metabolism in skeletal muscle of endurance-trained males and females. J Appl Physiol 47:787-91

42. Langfort J, Ploug T, Ihlemann J, Saldo M, Holm C, Galbo H 1999 Expression of hormone-sensitive lipase and its regulation by adrenaline in skeletal muscle. Biochem J 340 (Pt 2):459-65

43. Donsmark M, Langfort J, Holm C, Ploug T, Galbo H 2004 Regulation and role of hormone-sensitive lipase in rat skeletal muscle. Proc Nutr Soc 63:309-14

44. Enevoldsen LH, Stallknecht B, Langfort J, et al. 2001 The effect of exercise training on hormone-sensitive lipase in rat intra-abdominal adipose tissue and muscle. J Physiol 536:871-7

45. Enoksson S, Hagstrom-Toft E, Nordahl J, et al. 2005 Marked reutilization of free fatty acids during activated lipolysis in human skeletal muscle. J Clin Endocrinol Metab 90:1189-95

46. Oscai LB, Essig DA, Palmer WK 1990 Lipase regulation of muscle triglyceride hydrolysis. J Appl Physiol 69:1571-7

47. Randle P 1979 Molecular mechanisms regulating fuel selection in muscle. University Park Press, Baltimore

48. Mujika I, Padilla S 2000 Detraining: loss of training-induced physiological and performance adaptations. Part I: short term insufficient training stimulus. Sports Med 30:79-87

49. Gaspard UJ, Gottal JM, van den Brule FA 1995 Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 21:171-8

50. Bergman RN, Van Citters GW, Mittelman SD, et al. 2001 Central role of the adipocyte in the metabolic syndrome. J Investig Med 49:119-26

51. Boden G, Shulman GI 2002 Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32 Suppl 3:14-23

52. Arner P 2002 Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 18 Suppl 2:S5-9

53. Blaak EE 2003 Fatty acid metabolism in obesity and type 2 diabetes mellitus. Proc Nutr Soc 62:753-60

54. Kraemer FB, Patel S, Singh-Bist A, Gholami SS, Saedi MS, Sztalryd C 1993 Detection of hormone-sensitive lipase in various tissues. II. Regulation in the rat testis by human chorionic gonadotropin. J Lipid Res 34:609-16

55. Anderson LA, McTernan PG, Harte AL, Barnett AH, Kumar S 2002 The regulation of HSL and LPL expression by DHT and flutamide in human subcutaneous adipose tissue. Diabetes Obes Metab 4:209-13

56. Dicker A, Ryden M, Naslund E, et al. 2004 Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots. Diabetologia 47:420-8

57. Tikkanen MJ, Nikkila EA, Kuusi T, Sipinen SU 1982 High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 54:1113-7

58. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB, Jr., Levy RI 1983 The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 57:262-7

59. Price TM, O'Brien SN, Welter BH, George R, Anandjiwala J, Kilgore M 1998 Estrogen regulation of adipose tissue lipoprotein lipase--possible mechanism of body fat distribution. Am J Obstet Gynecol 178:101-7

60. Jensen MD, Martin ML, Cryer PE, Roust LR 1994 Effects of estrogen on free fatty acid metabolism in humans. Am J Physiol 266:E914-20

61. Zimmermann R, Strauss JG, Haemmerle G, et al. 2004 Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306:1383-6

62. Mathur U, Bartke A, Weisz J 1975 Effects of prolactin and LH on the activity of delta5-3beta hydroxy-steroid dehydrogenase, dihydro-orotic dehydrogenase, b-hydroxybutyrate

dehydrogenase and glucose-6-phosphate dehydrogenase in the testis of the dwarf mice. Indian J Physiol Pharmacol 19:58-64

63. Olpin SE 2004 Implications of impaired ketogenesis in fatty acid oxidation disorders. Prostaglandins Leukot Essent Fatty Acids 70:293-308

64. Gorski J, Oscai LB, Palmer WK 1990 Hepatic lipid metabolism in exercise and training. Med Sci Sports Exerc 22:213-21

65. Ohmori H, Kawai K, Yamashita K 1990 Enhanced ketone body uptake by perfused skeletal muscle in trained rats. Endocrinol Jpn 37:421-9

66. Holloszy JO, Kohrt WM, Hansen PA 1998 The regulation of carbohydrate and fat metabolism during and after exercise. Front Biosci 3:D1011-27

67. Stevenson JC 1996 Metabolic effects of the menopause and oestrogen replacement. Baillieres Clin Obstet Gynaecol 10:449-67

68. Spencer CP, Godsland IF, Stevenson JC 1997 Is there a menopausal metabolic syndrome? Gynecol Endocrinol 11:341-55

69. Morimoto S, Fernandez-Mejia C, Romero-Navarro G, Morales-Peza N, Diaz-Sanchez V 2001 Testosterone effect on insulin content, messenger ribonucleic acid levels, promoter activity, and secretion in the rat. Endocrinology 142:1442-7

70. El Seifi S, Green IC, Perrin D 1981 Insulin release and steroid-hormone binding in isolated islets of langerhans in the rat: effects of ovariectomy. J Endocrinol 90:59-67

71. Xu T, Wang X, Hou S, Zhu J, Zhang X, Huang X 2002 Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer. Chin Med J (Engl) 115:1336-40

72. Heymsfield SB, Gallagher D, Poehlman ET, et al. 1994 Menopausal changes in body composition and energy expenditure. Exp Gerontol 29:377-89

73. Mauras N, Hayes V, Welch S, et al. 1998 Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 83:1886-92

74. Mauras N, O'Brien KO, Klein KO, Hayes V 2000 Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 85:2370-7

75. Bhasin S, Woodhouse L, Storer TW 2003 Androgen effects on body composition. Growth Horm IGF Res 13 Suppl A:S63-71

76. Mayes JS, Watson GH 2004 Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev 5:197-216

77. Oben JE, Dils RR 2001 Prolactin-stimulated polymerization of acetyl-coA carboxylase in explants of mid-pregnant rat mammary gland. J Dairy Res 68:351-5

78. Mao J, Molenaar AJ, Wheeler TT, Seyfert HM 2002 STAT5 binding contributes to lactational stimulation of promoter III expressing the bovine acetyl-CoA carboxylase alpha-encoding gene in the mammary gland. J Mol Endocrinol 29:73-88

79. Phinney SD, Bistrian BR, Evans WJ, Gervino E, Blackburn GL 1983 The human metabolic response to chronic ketosis without caloric restriction: preservation of submaximal exercise capability with reduced carbohydrate oxidation. Metabolism 32:769-76

80. Khan-Dawood FS, Yang J, Dawood MY 1997 Immunohistological localization and expression of alpha-actin in the baboon (Papio anubis) corpus luteum. J Histochem Cytochem 45:71-7

81. Piccone CM, Brazeau GA, McCormick KM 2005 Effect of oestrogen on myofibre size and myosin expression in growing rats. Exp Physiol 90:87-93

82. Tipton CM, Matthes RD, Maynard JA, Carey RA 1975 The influence of physical activity on ligaments and tendons. Med Sci Sports 7:165-75

83. Schwall R, Schmelzer CH, Matsuyama E, Mason AJ 1989 Multiple actions of recombinant activin-A in vivo. Endocrinology 125:1420-3

84. Hinderliter AL, Sherwood A, Blumenthal JA, et al. 2002 Changes in hemodynamics and left ventricular structure after menopause. Am J Cardiol 89:830-3

85. Leon-Velarde F, Ramos MA, Hernandez JA, et al. 1997 The role of menopause in the development of chronic mountain sickness. Am J Physiol 272:R90-4

86. van den Beld A, Huhtaniemi IT, Pettersson KS, et al. 1999 Luteinizing hormone and different genetic variants, as indicators of frailty in healthy elderly men. J Clin Endocrinol Metab 84:1334-9

87. Johansen AT, Norman N 1991 Reproductive hormones during 42 days of maximal physical effort, low temperatures and general hardship. Arctic Med Res 50 Suppl 6:142-7

88. Bhasin S, Woodhouse L, Storer TW 2001 Proof of the effect of testosterone on skeletal muscle. J Endocrinol 170:27-38

89. Musaro A, Cusella De Angelis MG, Germani A, Ciccarelli C, Molinaro M, Zani BM 1995 Enhanced expression of myogenic regulatory genes in aging skeletal muscle. Exp Cell Res 221:241-8

90. Sciote JJ, Horton MJ, Zyman Y, Pascoe G 2001 Differential effects of diminished oestrogen and androgen levels on development of skeletal muscle fibres in hypogonadal mice. Acta Physiol Scand 172:179-87

91. Z'Berg C, Augsburger HR 2002 Differences of morphometrical parameters in hind limb muscle fibres between ovarectomized and sexually intact female dogs. Ann Anat 184:165-72

92. Rivero JL, Henckel P 1996 Muscle biopsy index for discriminating between endurance horses with different performance records. Res Vet Sci 61:49-54

93. Baker ER, Mathur RS, Kirk RF, Williamson HO 1981 Female runners and secondary amenorrhea: correlation with age, parity, mileage, and plasma hormonal and sex-hormone-binding globulin concentrations. Fertil Steril 36:183-7

94. Harber VJ 2000 Menstrual dysfunction in athletes: an energetic challenge. Exerc Sport Sci Rev 28:19-23

95. Warren MP, Goodman LR 2003 Exercise-induced endocrine pathologies. J Endocrinol Invest 26:873-8

96. Loucks AB, Verdun M 1998 Slow restoration of LH pulsatility by refeeding in energetically disrupted women. Am J Physiol 275:R1218-26

97. Loucks AB, Verdun M, Heath EM 1998 Low energy availability, not stress of exercise, alters LH pulsatility in exercising women. J Appl Physiol 84:37-46

98. Guezennec CY, Ferre P, Serrurier B, Merino D, Pesquies PC 1982 Effects of prolonged physical exercise and fasting upon plasma testosterone level in rats. Eur J Appl Physiol Occup Physiol 49:159-68

99. Bowen RL, Atwood CS 2004 Living and dying for sex. A theory of aging based on the modulation of cell cycle signaling by reproductive hormones. Gerontology 50:265-90

100. Keller P, Keller C, Steensberg A, Robinson LE, Pedersen BK 2005 Leptin gene expression and systemic levels in healthy men: effect of exercise, carbohydrate, interleukin-6, and epinephrine. J Appl Physiol 98:1805-12

101. Jurimae J, Jurimae T 2005 Leptin responses to short term exercise in college level male rowers. Br. J. Sports Med 39:6-9

102. Licinio J, Negrao AB, Mantzoros C, et al. 1998 Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women. Proc Natl Acad Sci U S A 95:2541-6

103. Einhorn L 1996 Testicular cancer, 4th Edition ed. Lippincott, Philadelphia

104. Howell SJ, Shalet SM 2002 Effect of cancer therapy on pituitary-testicular axis. Int J Androl 25:269-76

105. Petersen PM, Skakkebaek NE, Giwercman A 1998 Gonadal function in men with testicular cancer: biological and clinical aspects. Apmis 106:24-34; discussion 34-6

106. Yasuda Y, Fujita Y, Matsuo T, et al. 2003 Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24:1021-9

107. Cortes D, Thorup J, Visfeldt J 2003 Multinucleated spermatogonia in cryptorchid boys: a possible association with an increased risk of testicular malignancy later in life? Apmis 111:25-30; discussion 31